Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 6;8:735853. doi: 10.3389/fmed.2021.735853

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Moreira-Soto, Arguedas, Brenes, Buján, Corrales-Aguilar, Díaz, Echeverri, Flores-Díaz, Gómez, Hernández, Herrera, León, Macaya, Kühne, Molina-Mora, Mora, Sanabria, Sánchez, Sánchez, Segura, Segura, Solano, Soto, Stynoski, Vargas, Villalta, Reusken, Drosten, Gutiérrez, Alape-Girón and Drexler.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

In vitro neutralizing potency of (A) Anti-S1 (S1 SARS-CoV-2 recombinant protein) and (B) Anti-Mix (mixture of S1, N, and SEM mosaic SARS-CoV-2 recombinant proteins of Wuhan-Hu-1, Accession N YP_009724390.1) polyclonal antibodies purified from the plasma of hyperimmunized horses against different SARS-CoV-2 variants of concern (VoC) and an early isolate, named using WHO and Pango/Nextrain designations (strains used = GERMANY/GISAID EPI_ISL 406862, BetaCoV/ChVir21652, hCoV-19/Aruba_11401/2021, hCoV-19/Netherlands/NoordHolland_10915/2021, BetaCoV/ChVir22131/B.1.351/501Y.V2, SARS-CoV-2/CSpecVir25702_4/B.1.617.2 p.1, VS 09.07.2021 acquired from https://www.european-virus-archive.com/evag-news/sars-cov-2-collection). The inhibitory concentration (IC₅₀) in plaque reduction neutralization tests (PRNT) was calculated using a non-linear regression analysis in the GraphPadPrism 5 software. Potencies (IC₅₀) were not statistically different among viral variants with the Anti-Mix formulation, and the null hypothesis was not rejected, meaning the IC₅₀ was equal in all datasets. The potencies (IC₅₀) for the Anti-S1 formulations were significantly different, meaning the IC₅₀ differed between formulations, but only when the delta VoC was added (denoted by an asterisk). Dotted lines denote the mean minimum and maximum concentrations and vertical solid lines denote 95% confidence intervals for both formulations.